復宏漢霖(02696.HK):注射液HLX01三期臨床結果顯示聯合療法有效
復宏漢霖(02696.HK)公布,自主開發的利妥昔單抗注射液(HLX01),用於治療類風濕關節炎的第三期臨床試驗數據,將於中華醫學會第二十五次全國風濕病學學術會議上發表。
公司指出,臨床結果顯示HLX01聯合甲氨蝶呤相較於安慰劑,在甲氨蝶呤治療應答不完全(MTX-IR)的中國中重度活動性類風濕關節炎(RA)受試者中具有顯著的臨床療效和良好的安全性,證明HLX01聯合MTX是一種可耐受、安全、有效的治療選擇。(gc/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.